Title :

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network

Author(s) :

Mosbah, H [Auteur]
Vantyghem, M [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Nobécourt, E [Auteur]
Andreelli, F [Auteur]
Archambeaud, F [Auteur]
Bismuth, E [Auteur]
Briet, C [Auteur]
MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale [MITOVASC]
Cartigny, M [Auteur]
Donadille, B [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Daguenel, A [Auteur]
Fichet, M [Auteur]
Gautier, J [Auteur]
Janmaat, S [Auteur]
Jéru, I [Auteur]
Legagneur, C [Auteur]
Leguier, L [Auteur]
Maitre, J [Auteur]
Mongeois, E [Auteur]
Poitou, C [Auteur]
Renard, Eric [Auteur]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Reznik, Y [Auteur]
Spiteri, A [Auteur]
Travert, F [Auteur]
Vergès, B [Auteur]
Zammouri, J [Auteur]
Vigouroux, Corinne [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [ICAN]
Vatier, C [Auteur]

Journal title :

Diabetes, Obesity and Metabolism

Publisher :

Wiley

Publication date :

2022-04-22

ISSN :

1462-8902

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Endocrinologie et métabolisme

English abstract : [en]

Aims: To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromestreated with metreleptin in a national reference network, in a real-life setting.Patients and Methods: Clinical and ...
Show more >Aims: To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromestreated with metreleptin in a national reference network, in a real-life setting.Patients and Methods: Clinical and metabolic data from patients receiving metreleptin in France wereretrospectively collected, at baseline, one year and at the latest follow-up during treatment.Results: Forty-seven patients with lipodystrophy including generalized lipodystrophy (GLD, n=28) andpartial lipodystrophy (PLD, n=19) received metreleptin over the last decade. At baseline, age was 29.3[16.6-47.6] (years, median [interquartile range]); BMI 23.8 kg/m2 [21.2-25.7]; serum leptin 3.2 [1.0-4.9] ng/mL); 94% of patients had diabetes (66% insulin-treated), 53% hypertension, and 87%dyslipidemia. Metreleptin therapy, administered during 31.7 [14.2-76.0] months, was ongoing in 77%of patients at the latest follow-up. In patients with GLD, HbA1c (%) and fasting triglycerides (mmol/L)significantly decreased from baseline to one year-metreleptin treatment, from 8.4 [6.5-9.9] to 6.8 [5.6-7.4], and 3.6 [1.7-8.5] to 2.2 [1.1-3.7] respectively (p<0.001), with a sustained efficacy thereafter. Inpatients with PLD, HbA1c (%) was not significantly modified from 7.7 [7.1-9.1] at baseline vs 7.7 [7.4-9.5] at one-year), and the decrease in fasting triglycerides (mmol/L), from 3.3 [1.9-9.9] to 2.5 [1.6-5.3],p<0.01) was not confirmed at the latest assessment (5.2 [2.2-11.3]). However, among PLD patients, atone-year, 61 % were responders regarding glucose homeostasis, with lower baseline leptin levelscompared to non-responders, and 61% were responders regarding triglyceridemia. Liver enzymessignificantly decreased only in the GLD group.Conclusions: In this real-life setting study, metabolic outcomes are improved under metreleptintherapy in patients with GLD. The therapeutic indication of metreleptin needs to be clarified in patientswith PLD.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL